FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock
This article was originally published in The Pink Sheet Daily
Executive Summary
Policy shifts to address opioid abuse epidemic include changes to immediate-release opioid labeling, updated REMS requirements, and a new advisory committee.
You may also be interested in...
The Short And Controversial Life Of Zohydro Comes To An End
US FDA’s approval of the opioid over resounding opposition of an advisory committee has haunted the agency, and it has imperiled both of Robert Califf’s nominations to be commissioner. The latest company to own Zohydro stopped selling it and FDA withdrew approval of its NDA.
Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders
Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.
Potential For Califf’s Second US FDA Commissioner Term Surprises, Excites Stakeholders
Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.